{
    "clinical_study": {
        "@rank": "129275", 
        "arm_group": [
            {
                "arm_group_label": "Adjuvant chemotherapy with paclitaxel and nedaplatin", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation"
            }, 
            {
                "arm_group_label": "Observation", 
                "arm_group_type": "No Intervention", 
                "description": "Patients will be followed up without adjuvant chemotherapy after concurrent chemoradiation"
            }
        ], 
        "brief_summary": {
            "textblock": "By this clinical trial, the investigators are trying to give an answer to such a question.\n      Whether NPC patients staged N2-3M0 need adjuvant chemotherapy consisting of paclitaxel and\n      platinum after concurrent chemoradiation?"
        }, 
        "brief_title": "NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Nasopharyngeal Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Nasopharyngeal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Recent research (Lancet Oncology 2012)shows that no survival benefits were achieved by\n      adding adjuvant chemotherapy after concurrent chemoradiation in patients with locoregionally\n      advanced NPC. But in patients with even high risk of distant metastasis(staged N2-3M0),is\n      adjuvant chemotherapy necessary?"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. pathologically confirmed untreated NPC patients staged N2-3M0\n\n          2. age: 18y - 65y\n\n          3. with MRI examinations\n\n          4. ECOG\u22642\n\n          5. with written consent\n\n        Exclusion Criteria:\n\n          1. without a second cancer\n\n          2. pregnancy\n\n          3. with other severe diseases(blood,liver ,kidney or heart diseases)\n\n          4. could not staged properly\n\n          5. without written consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01694576", 
            "org_study_id": "NPC-N23-RCT", 
            "secondary_id": "JSCC-RCT01"
        }, 
        "intervention": {
            "arm_group_label": "Adjuvant chemotherapy with paclitaxel and nedaplatin", 
            "description": "Patients receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation", 
            "intervention_name": "Adjuvant chemotherapy with paclitaxel and nedaplatin", 
            "intervention_type": "Drug", 
            "other_name": "Adjuvant chemotherapy"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Nedaplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Nasopharyngeal carcinoma staged N2-3M0", 
            "Adjuvant chemotherapy"
        ], 
        "lastchanged_date": "March 21, 2014", 
        "location": {
            "contact": {
                "email": "xu016@sohu.com", 
                "last_name": "Jianhua Xu, M.D.", 
                "phone": "15805161106"
            }, 
            "facility": {
                "address": {
                    "city": "Nanjing", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "210009"
                }, 
                "name": "Jiangsu Cancer Hospital"
            }, 
            "investigator": {
                "last_name": "Jianhua Xu, M.D.", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Adjuvant Chemotherapy or Not for NPC Patients Staged N2-3M0 After Concurrent Chemotherapy :a Phase \u2161 Study", 
        "other_outcome": {
            "measure": "distant metastasis free survival", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "overall_contact": {
            "email": "xu016@sohu.com", 
            "last_name": "Jianhua Xu, M.D.", 
            "phone": "15805161106"
        }, 
        "overall_official": {
            "affiliation": "Department of Radiotherapy,Jiangsu Cancer Hospital", 
            "last_name": "Xia He, M.D. and PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "treatment toxicity based on a CTCAE3.0 grading system", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01694576"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Jiangsu Cancer Institute & Hospital", 
            "investigator_full_name": "Dr. Xia He", 
            "investigator_title": "Director of the department of radiotherapy", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "progress free survival", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "source": "Jiangsu Cancer Institute & Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Cancer Institute & Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}